Form 4: Dianthus Therapeutics, Inc. /DE/ Executive Sells Shares
Insider Transaction (Form 4)
Simrat Randhawa, EVP, Head of R&D of Dianthus Therapeutics, Inc. /DE/, sold 23,124 shares of common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 7,500 Common Stock at $17.88 ($134,100) on September 1, 2026; holds 11,500 after (Direct).
- Option exercise/conversion: acquired 6,249 Common Stock at $21.77 ($136,041) on September 1, 2026; holds 17,749 after (Direct).
- Option exercise/conversion: acquired 9,375 Common Stock at $22.07 ($206,906) on September 1, 2026; holds 27,124 after (Direct).
- Open-market sale: disposed of 2,600 Common Stock at $105.19 ($273,494) on September 1, 2026; holds 24,524 after (Direct).
- Open-market sale: disposed of 7,215 Common Stock at $106.25 ($766,594) on September 1, 2026; holds 17,309 after (Direct).
- Open-market sale: disposed of 13,309 Common Stock at $106.74 ($1,420,603) on September 1, 2026; holds 4,000 after (Direct).
- Option exercise/conversion: disposed of 7,500 Stock Option (Right to Buy) on September 1, 2026; holds 56,776 after (Direct).
- Option exercise/conversion: disposed of 6,249 Stock Option (Right to Buy) on September 1, 2026; holds 41,676 after (Direct).
- Option exercise/conversion: disposed of 9,375 Stock Option (Right to Buy) on September 1, 2026; holds 87,500 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,460,690 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Simrat Randhawa — Officer (EVP, Head of R&D)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 7,500 | $18 | $134.1K | 11,500 |
| 2026-09-01 | Option exercise/conversion | Common Stock | 6,249 | $22 | $136.0K | 17,749 |
| 2026-09-01 | Option exercise/conversion | Common Stock | 9,375 | $22 | $206.9K | 27,124 |
| 2026-09-01 | Open-market sale | Common Stock | 2,600 | $105 | $273.5K | 24,524 |
| 2026-09-01 | Open-market sale | Common Stock | 7,215 | $106 | $766.6K | 17,309 |
| 2026-09-01 | Open-market sale | Common Stock | 13,309 | $107 | $1.4M | 4,000 |
| 2026-09-01 | Option exercise/conversion | Stock Option (Right to Buy) | 7,500 | — | — | 56,776 |
| 2026-09-01 | Option exercise/conversion | Stock Option (Right to Buy) | 6,249 | — | — | 41,676 |
| 2026-09-01 | Option exercise/conversion | Stock Option (Right to Buy) | 9,375 | — | — | 87,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (7,500 shares) |
| 2026-09-01 | Option exercise/conversion (6,249 shares) |
| 2026-09-01 | Option exercise/conversion (9,375 shares) |
| 2026-09-01 | Open-market sale (2,600 shares) |
| 2026-09-01 | Open-market sale (7,215 shares) |
| 2026-09-01 | Open-market sale (13,309 shares) |
| 2026-09-01 | Option exercise/conversion (7,500 shares) |
| 2026-09-01 | Option exercise/conversion (6,249 shares) |
| 2026-09-01 | Option exercise/conversion (9,375 shares) |
Keywords
insider transaction, Form 4, DNTH, Dianthus Therapeutics, Inc. /DE/, bearish, Simrat Randhawa
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.